• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 6, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study examines private insurance claims for naloxone prescriptions

Bioengineer by Bioengineer
May 3, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: A study based on a national database of private insurance claims suggests few patients at high risk of opioid overdose receive prescriptions for naloxone, which can reverse an overdose, during encounters with the health care system from hospitalizations and emergency department visits to physician visits. Among 138,108 high-risk patients, only 2,135 (1.5 percent) were prescribed naloxone. A greater likelihood of receiving naloxone was associated with prior diagnoses of opioid misuse or dependence and overdose compared to those diagnoses without overdose. A prior diagnosis of opioid overdose alone was associated with decreased likelihood of receiving naloxone compared with a prior diagnosis of opioid misuse or dependence without overdose. Study authors acknowledge their results underestimate the distribution and use of naloxone because many patients get it through programs where insurance isn’t billed or patients may pay out of pocket. The study findings also may not be generalized to patients covered by Medicaid, some Medicare plans or those who are uninsured. Still, understanding barriers, such as a lack of awareness of local laws, to physician prescribing of naloxone to high-risk patients is important so that health care encounters aren’t missed opportunities to provide the medication.

Authors: Mai T. Pho, M.D., M.P.H., of the University of Chicago Medicine, and coauthors

(doi: 10.1001/jamanetworkopen.2019.3209)

Editor’s Note: The article contains funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Embed this link to provide your readers free access to the full-text article: This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2019.3209?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050319

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. Every Friday, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Media Contact
Ashley Heher

[email protected]

Tags: DrugsHealth Care Systems/ServicesInsuranceMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Lynch Syndrome Linked to Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor

September 6, 2026

AI Advances Body Composition Analysis from Pixels to Prediction

September 6, 2026

Sleep apnea disrupts autonomic control during REM sleep in type 1 diabetes

September 6, 2026

Glucose monitoring linked to weight and blood sugar changes in type 1 diabetes

September 6, 2026
Please login to join discussion

POPULAR NEWS

  • GenAI policies and trends at Australian and New Zealand universities

    29 shares
    Share 12 Tweet 7
  • New lethal mouse model of Coxsackievirus B1 enables antiviral drug testing

    29 shares
    Share 12 Tweet 7
  • New field-testing methods reveal stiffness of asphalt pavement layers

    29 shares
    Share 12 Tweet 7
  • Lynch Syndrome Linked to Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

GenAI policies and trends at Australian and New Zealand universities

New lethal mouse model of Coxsackievirus B1 enables antiviral drug testing

New field-testing methods reveal stiffness of asphalt pavement layers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.